These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 8356590)
1. The hemodynamic effects of intraoperative injection of muromonab CD3. Robinson ST; Barry JM; Norman DJ Transplantation; 1993 Aug; 56(2):356-8. PubMed ID: 8356590 [TBL] [Abstract][Full Text] [Related]
2. [Muromonab CD3 (Orthoclone OKT3) for the prophylaxis of heart allograft rejection. Hemodynamics and respiratory tolerance]. Guinvarc'h A; Fouillard A; Amrein C; Guillemain R; Chevalier P; Acar C; Couetil JP; Vulser C Ann Fr Anesth Reanim; 1995; 14(4):331-5. PubMed ID: 8572388 [TBL] [Abstract][Full Text] [Related]
3. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Vallhonrat H; Williams WW; Cosimi AB; Tolkoff-Rubin N; Ginns LC; Wain JC; Preffer F; Olszak I; Wee S; Delmonico FL; Pascual M Transplantation; 1999 Jan; 67(2):253-8. PubMed ID: 10075589 [TBL] [Abstract][Full Text] [Related]
4. The effects of intraoperative administration of OKT3 during renal transplantation. Beilman GJ; Shield CF; Hughes JD; Kelley HK; Ward LG; Beck D Transplantation; 1993 Mar; 55(3):490-3. PubMed ID: 8456466 [TBL] [Abstract][Full Text] [Related]
5. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial. Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510 [TBL] [Abstract][Full Text] [Related]
6. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115 [TBL] [Abstract][Full Text] [Related]
7. Administration of OKT3 in the operating room. Robinson ST Transplant Proc; 1993 Apr; 25(2 Suppl 1):41-2. PubMed ID: 8465422 [No Abstract] [Full Text] [Related]
8. Consequences of OKT3 administration via continuous infusion as compared to bolus infusion. ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Hack CE Transplant Proc; 1996 Dec; 28(6):3217-20. PubMed ID: 8962246 [No Abstract] [Full Text] [Related]
9. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients. Kupin W; Venkat KK; Ikemiyashiro D; Ocdol H; Mozes M; Anaise D; Johnson C Transplant Proc; 1993 Feb; 25(1 Pt 1):572-4. PubMed ID: 8438419 [No Abstract] [Full Text] [Related]
10. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506 [TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063 [TBL] [Abstract][Full Text] [Related]
12. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI; Goa KL Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551 [TBL] [Abstract][Full Text] [Related]
13. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3). Hartnick CJ; Cohen AF; Smith RV Ann Otol Rhinol Laryngol; 1997 Aug; 106(8):640-2. PubMed ID: 9270425 [TBL] [Abstract][Full Text] [Related]
14. Modulation of peripheral blood T-lymphocytes in kidney transplant recipients treated with low dose OKT3 therapy. Galante NZ; Câmara NO; Kallás EG; Salomão R; Pacheco-Silva A Immunol Lett; 2004 Jan; 91(1):75-7. PubMed ID: 14757373 [TBL] [Abstract][Full Text] [Related]
15. Acute thrombosis of the renal transplant artery after a single dose of OKT3. Shankar R; Bastani B; Salinas-Madrigal L; Sudarshan B Am J Nephrol; 2001; 21(2):141-4. PubMed ID: 11359022 [TBL] [Abstract][Full Text] [Related]
16. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation. Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356 [TBL] [Abstract][Full Text] [Related]
17. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643 [TBL] [Abstract][Full Text] [Related]
18. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect. Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580 [TBL] [Abstract][Full Text] [Related]
19. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Massicotte L; Perrault MA; Denault AY; Klinck JR; Beaulieu D; Roy JD; Thibeault L; Roy A; McCormack M; Karakiewicz P Transplantation; 2010 Apr; 89(8):920-7. PubMed ID: 20216483 [TBL] [Abstract][Full Text] [Related]